Koers Pieris Pharmaceuticals Inc OTC Bulletin Board
Aandelen
PIRS
US7207951036
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- | - |
Omzet 2022 | 25,9 mln. 0 23,83 mln. | Omzet 2023 | 42,81 mln. 0 39,39 mln. | Marktkapitalisatie | 17,99 mln. 0 16,56 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -33 mln. - -30,37 mln. | Nettowinst (verlies) 2023 | -24 mln. - -22,08 mln. | EV/omzet 2022 | 1,21 x |
Nettoliquiditeiten 2022 | 46,07 mln. 0 42,39 mln. | Nettoliquiditeiten 2023 | 26,37 mln. 0 24,26 mln. | EV/omzet 2023 | -0,2 x |
K/w-verhouding 2022 |
-2,32
x | K/w-verhouding 2023 |
-0,67
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 92,57% |
Recentste transcriptie over Pieris Pharmaceuticals Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Yoder
CEO | Chief Executive Officer | 48 | 01-01-10 |
Thomas Bures
DFI | Director of Finance/CFO | 49 | 01-12-17 |
Kayti Aviano
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 59 | 20-09-16 | |
James Geraghty
CHM | Chairman | 69 | 22-05-17 |
Michael Richman
BRD | Director/Board Member | 63 | 17-12-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,42% | 114 mld. | |
+11,84% | 104 mld. | |
-14,15% | 22,41 mld. | |
-1,05% | 22,28 mld. | |
-5,29% | 19,07 mld. | |
-38,29% | 18 mld. | |
-4,16% | 17,89 mld. | |
+7,99% | 14,28 mld. | |
+36,24% | 12,55 mld. |
- Beurs
- Aandelen
- Koers PIRS
- Koers PIRS